Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Different Types of Intermittent Fasting Interventions on Metabolic Health in Healthy Individuals (EDIF): A Randomised Trial with a Controlled-Run in Phase.
Herz D, Karl S, Weiß J, Zimmermann P, Haupt S, Zimmer RT, Schierbauer J, Wachsmuth NB, Erlmann MP, Niedrist T, Khoramipour K, Voit T, Rilstone S, Sourij H, Moser O. Herz D, et al. Among authors: karl s. Nutrients. 2024 Apr 10;16(8):1114. doi: 10.3390/nu16081114. Nutrients. 2024. PMID: 38674802 Free PMC article. Clinical Trial.
Is the next generation of mosquito nets surviving expectations?
Moore S, Karl S. Moore S, et al. Among authors: karl s. Lancet Infect Dis. 2024 Feb 21:S1473-3099(24)00073-2. doi: 10.1016/S1473-3099(24)00073-2. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38401553 No abstract available.
A cross-sectional study to ascertain malaria prevalence among asymptomatic travellers arriving on the Lihir Group of Islands, Papua New Guinea: implications for elimination efforts.
Millat-Martínez P, Baro B, Kasian B, Lorry L, Sanz S, Wali C, Raulo S, Elizah A, Koleala T, Kaius-Ome M, Karl S, Mitjà O, Laman M, Pomat W, Bassat Q. Millat-Martínez P, et al. Among authors: karl s. Malar J. 2023 Nov 29;22(1):364. doi: 10.1186/s12936-023-04804-y. Malar J. 2023. PMID: 38031175 Free PMC article.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
264 results